C.T
Share This Job!
Corcept is leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators.
In 2012, we received FDA approval of Korlym® (mifepristone), the first approved treatment for hypercortisolism (Cushing’s syndrome).
Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat serious diseases. With more than 30 ongoing studies across a wide range of disease areas, including endocrinology, oncology, metabolism, and neurology, we remain dedicated to advancing the possibilities of cortisol modulation.
What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease.
C.T
Share This Job!
The Medical Science Liaison – Oncology engages with clinicians and organizations to support Natera’s oncology products.
C.T
Corcept Therapeutics
Join Corcept as an Oncology Medical Science Liaison to engage with thought leaders and support innovative cancer treatments.
C.T
Corcept Therapeutics
Join Corcept as an Oncology Medical Science Liaison to engage with thought leaders and support innovative oncology research.
T.P.A
Telix Pharmaceuticals (Americas)
Join Telix Pharmaceuticals as a Medical Science Liaison focusing on neuro oncology, engaging with key opinion leaders and supporting clinical research.
The Senior Medical Science Liaison will engage with oncology healthcare providers and deliver presentations on Catalyst’s products.